Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022)

Jazz Pharmaceuticals' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $116000.0 for Q3 2022.

• In Q3 2022, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0; the TTM figure through Sep 2022 stood at $116000.0 (down 88.24% YoY), while the FY2021 annual figure was $463000.0, down 80.0% from the prior year.
• Non-Current Deffered Revenue was $116000.0 for Q3 2022 at Jazz Pharmaceuticals, down from $231000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $13.6 million in Q1 2018 to a low of $116000.0 in Q3 2022.
• Historically, Non-Current Deffered Revenue has averaged $4.8 million across 5 years, with a median of $3.6 million in 2020.
• The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue sank 38.41% in 2019, then tumbled 88.24% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $9.6 million in 2018, then plunged by 49.26% to $4.9 million in 2019, then plunged by 52.38% to $2.3 million in 2020, then plunged by 80.0% to $463000.0 in 2021, then plunged by 74.95% to $116000.0 in 2022.
• The last three Non-Current Deffered Revenue figures came in at $116000.0 (Q3 2022), $231000.0 (Q2 2022), and $347000.0 (Q1 2022), per Business Quant data.